Competitive Edge | Explore Merus's unique multispecific antibody platform and its potential to revolutionize cancer treatment across various indications, including colorectal cance |
Market Potential | Analysts project significant revenue growth, with estimates reaching $525.9 million by 2027, as Merus pursues accelerated approval for its groundbreaking therapy |
Clinical Triumph | Phase 2 trials reveal strong overall response rates and survival outcomes, surpassing current treatment benchmarks and showcasing petosemtamab's potential |
Promising Pipeline | Merus's lead candidate petosemtamab shows impressive efficacy in treating Head and Neck Squamous Cell Carcinoma, positioning the company as a potential market leade |
Metrics to compare | MRUS | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipMRUSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −2.0x | −0.4x | |
PEG Ratio | 0.00 | 0.06 | 0.00 | |
Price / Book | 0.0x | 3.5x | 2.6x | |
Price / LTM Sales | 0.0x | 5.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 1,225.3% | 54.5% | |
Fair Value Upside | Unlock | 0.9% | 7.2% | Unlock |